Prostate cancer is the second most common cancer in men globally, with 1.4 million new cases diagnosed each year. Early detection dramatically improves survival rates, yet current screening methods like the PSA test have a false-positive rate as high as 70%, leading to unnecessary biopsies, patient anxiety, and wasted healthcare resources. EDX Medical Group's AI 'Supertest' is designed to change that equation.
The Problem: Prostate Cancer Screening Is Inaccurate
The Prostate-Specific Antigen (PSA) blood test has been the primary screening tool for prostate cancer for decades. But PSA levels can be elevated for many non-cancerous reasons, including benign prostate enlargement, infection, and even vigorous exercise. This leads to a staggering number of false positives, which in turn trigger invasive biopsies that carry their own risks of infection, bleeding, and psychological distress.
On the flip side, PSA tests also miss some aggressive cancers, creating false negatives that delay critical treatment. The medical community has long sought a more accurate, less invasive screening method that can distinguish between clinically significant cancer and harmless conditions. Traditional diagnostic pathways are expensive, slow, and burdensome for both patients and healthcare systems.
The Solution: What Is EDX Medical Group's AI 'Supertest'?
EDX Medical Group's AI 'Supertest' is an AI-driven diagnostic test developed by EDX Medical Group that uses advanced machine learning algorithms to analyse biomarker data and deliver highly accurate prostate cancer risk assessments. By combining multiple biomarkers and applying AI pattern recognition, the Supertest significantly reduces false positives and false negatives compared to traditional PSA testing, helping clinicians make better-informed decisions about when biopsies are truly warranted.
Visit EDX Medical Group's AI 'Supertest' to learn more about the technology, or check the EDX Medical Group's AI 'Supertest' details & alternatives page for additional information.
Key Features
| Feature | Details |
|---|---|
| AI-Powered Analysis | Machine learning algorithms analyse multiple biomarkers simultaneously for higher accuracy |
| Reduced False Positives | Significantly fewer unnecessary biopsy referrals compared to PSA alone |
| Multi-Biomarker Approach | Combines PSA with additional biomarkers for a comprehensive risk assessment |
| Non-Invasive | Based on blood test analysis, no additional invasive procedures for the screening step |
| Clinician Dashboard | Clear risk stratification reports for healthcare providers to guide treatment decisions |
| Clinical Validation | Developed using large clinical datasets and validated in peer-reviewed studies |
| Integration Ready | Designed to integrate into existing clinical laboratory workflows |
Getting Started
Step 1: Clinician Assessment
The Supertest is ordered through healthcare providers, not directly by consumers. Your urologist or GP evaluates whether you are a candidate based on factors like age, family history, and prior PSA results.
Step 2: Blood Sample Collection
A standard blood draw is taken at a clinical laboratory. The sample is analysed for multiple biomarkers beyond just PSA. No special preparation is typically required beyond what a standard blood test demands.
Step 3: AI Analysis and Reporting
The AI engine processes the biomarker data and generates a risk stratification report. This report provides the clinician with a clear assessment of whether the patient is at low, intermediate, or high risk for clinically significant prostate cancer.
Step 4: Clinical Decision
Based on the Supertest results, the clinician and patient can make a more informed decision about whether to proceed with a biopsy or continue monitoring. This reduces unnecessary procedures while ensuring truly at-risk patients receive timely intervention.
Real-World Use Cases
Reducing Unnecessary Biopsies
Hospitals and urology clinics use the Supertest to filter PSA-positive patients, identifying which elevations are likely benign and which warrant further investigation. This can reduce biopsy rates by a significant percentage while maintaining or improving cancer detection rates.
Population Screening Programs
Public health programmes considering large-scale prostate cancer screening can use the Supertest as a second-line filter after PSA, dramatically improving the cost-effectiveness and accuracy of screening campaigns.
High-Risk Patient Monitoring
Men with a family history of prostate cancer or those on active surveillance for low-grade cancer benefit from more precise monitoring. The Supertest provides nuanced risk data that helps clinicians decide when intervention is needed versus when continued observation is safe.
Pricing
| Aspect | Details |
|---|---|
| Direct Consumer Purchase | Not available; ordered through healthcare providers |
| Insurance Coverage | Coverage varies by region and insurer; check with your provider |
| Cost to Clinics | Pricing is negotiated with healthcare institutions and laboratory networks |
Pros and Cons
Pros
- Significantly higher accuracy than PSA testing alone
- Reduces unnecessary biopsies and associated patient burden
- Non-invasive screening step based on a standard blood draw
- AI analysis provides objective, reproducible risk stratification
- Clinically validated with peer-reviewed evidence
Cons
- Not available as a direct-to-consumer test; requires clinician involvement
- Limited availability depending on region and healthcare network
- Insurance coverage is not yet universal
- Does not replace biopsy for definitive diagnosis; it is a risk stratification tool
How EDX Medical Group's AI 'Supertest' Compares
Compared to the standard PSA test, the Supertest offers dramatically improved specificity, meaning fewer healthy men undergo unnecessary biopsies. Against other advanced screening tests like the 4Kscore or SelectMDx, the Supertest leverages AI-driven multi-biomarker analysis that may provide more nuanced risk stratification, though head-to-head comparison data continues to evolve.
Ready to Get Started?
If you or a loved one faces prostate cancer screening decisions, ask your urologist about AI-enhanced diagnostics. Learn more about EDX Medical Group's AI 'Supertest' and the science behind smarter cancer detection. Or explore EDX Medical Group's AI 'Supertest' details, alternatives & reviews for additional context and comparisons.
FAQs
Is the Supertest a replacement for biopsy?
No. The Supertest is a risk stratification tool that helps determine whether a biopsy is warranted. If the Supertest indicates high risk, a biopsy is still the gold standard for definitive diagnosis.
Can I order this test myself?
The Supertest is a clinical diagnostic tool ordered by healthcare providers. Speak with your urologist or GP about whether it is available and appropriate for your situation.
How accurate is the AI analysis?
Clinical studies report significantly improved sensitivity and specificity compared to PSA alone. Exact accuracy figures vary by study and population, so consult the latest published research or ask your clinician for current performance data.
Is it available outside the UK?
Availability is expanding. EDX Medical Group is working to bring the Supertest to additional markets. Check their website or ask your healthcare provider about current regional availability.
Related Articles
Last updated: February 2026
